Malini P L, Ambrosioni E, Bracchetti D, Magnani B
Int J Clin Pharmacol Biopharm. 1979 Oct;17(10):396-403.
The clinical efficacy of Aprindine, a new antiarrhythmic agent was tested in 37 patients with ventricular and supraventricular arrhythmias. The drug was shown to be effective - disappearance or prevention of relapse of the arrhythmia - in 80% of the cases with ventricular tachycardia, and in 67.7% of the cases with premature ventricular beats. No judgement was possible for supraventricular tachycardia due to the small number of patients. Effectivness of Aprindine was found to be related more closely to the administered dose expressed in mg/kg body weight than to plasma level in steady-state. Discontinuation of therapy was necessary in 5 cases due to the appearance of side effects (tremor and dizziness). Side effects were not found to be in relation with plasma levels or administered dose. In the period of observation (2 months) no effects on blood cells were noticed.
对37例室性和室上性心律失常患者测试了一种新型抗心律失常药物安搏律定的临床疗效。结果显示，该药对80%的室性心动过速病例以及67.7%的室性早搏病例有效，即心律失常消失或预防复发。由于患者数量较少，无法对室上性心动过速作出评价。发现安搏律定的有效性与以毫克/千克体重表示的给药剂量关系更为密切，而非与稳态血浆水平相关。5例患者因出现副作用（震颤和头晕）而必须停药。未发现副作用与血浆水平或给药剂量有关。在观察期（2个月）内，未注意到对血细胞有影响。
